LUCIGEN CORPORATION — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Next-generation sequencing (NGS) platforms are fundam
LUCIGEN CORPORATION — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $224,925
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA14-071
- NAICS
- —
- Place of performance
- WI
- Period
- —
Description
DESCRIPTION (provided by applicant): Next-generation sequencing (NGS) platforms are fundamentally altering genetic and genomic research by providing massive amounts of data in a low-cost, high-throughput format. The main drawback of existing technologies is the short sequence read lengths they produce. Existing library prep methods are also constrained in producing short inserts of only a few kb. As a result, de novo assembly of genomes is not practical with short read NGS technologies alone. Even with a high quality reference human genome, resequencing and assembly of new human genomes is a significant challenge when analyzing complex genomic regions. Haplotyping across more than a few kb is not achieved without resorting to cloned DNA. New tools that bridge the gap between massively parallel short read sequencing technologies (lt1,500 bases) and the need for large scaffolds gt 20 kb to assemble a genome are clearly needed. The SBIR Phase I grant proposal New Tools for Structural Variation Analysis, De N